NCT07428954 2026-02-24
LegitHealthSAN
AI Labs Group S.L
Completed
Clinical Trials
26 trialsNCT07256015 2025-12-01
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Bristol-Myers Squibb
Recruiting
NCT03284879 2025-09-08
Post-Marketing Surveillance Study of OTEZLA
Amgen
Completed
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT06989216 2025-05-25
DermaFlow
HJN Sverige AB/Neko Health
Recruiting
NCT06952465 2025-05-01
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
Bristol-Myers Squibb
Active not recruiting
NCT06583395 2024-11-01
QUANTUM
VitaMed Research LLC
Enrolling by invitation
NCT03721172 2024-05-29
ADVANCE
Amgen
Phase 3 Completed
NCT05635266 2024-05-07
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Recruiting
NCT02762955 2021-09-08
CALYPSO
Biocad
Phase 3 Completed
NCT00885196 2020-12-22
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Novartis
Phase 2 Completed
NCT01490632 2019-09-27
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01961609 2019-03-18
SIGNATURE
Novartis
Phase 3 Completed
NCT01582932 2019-01-22
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Mayne Pharma International Pty Ltd
Phase 1 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT03424629 2018-04-20
Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
Tianjin Ever Union Biotechnology Co., Ltd.
Phase 1 Unknown
NCT02196701 2018-03-19
CLEAR
AbbVie
Phase 3 Completed
NCT01163253 2017-06-26
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Terminated
NCT01313221 2017-03-15
REFINE
Amgen
Phase 3 Completed
NCT01831466 2015-11-25
Tofacitinib Ointment For Chronic Plaque Psoriasis
Pfizer
Phase 2 Completed
NCT01519089 2015-08-13
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
Phase 3 Completed
NCT01276639 2014-09-19
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT00111449 2013-05-15
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Amgen
Phase 3 Completed
NCT01126619 2012-10-25
A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis
Abbott
Completed